St. Jude Medical

The Devon Group Expands Partner Program, Teams Up with Sara in the City Events

Retrieved on: 
Wednesday, February 28, 2024

RED BANK, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Global technology public relations leader The Devon Group today shared news of its partnership program, welcoming a new alliance with strategic events planning firm, Sara in the City .

Key Points: 
  • RED BANK, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Global technology public relations leader The Devon Group today shared news of its partnership program, welcoming a new alliance with strategic events planning firm, Sara in the City .
  • Led by founder Sara Heald, DMCP, Sara in the City creates memorable experiences for companies that are planning meetings, exhibiting at conferences and hosting events.
  • Sara in the City’s services include event consultation, event design and planning, event management, meeting planning, destination management and event transportation and logistics.
  • Kate Achille, Managing Partner of The Devon Group, shared, “The events space has changed dramatically over the last few years.

NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, November 14, 2023

EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has appointed medtech executive Christopher R. Volker as Chief Operating Officer.

Key Points: 
  • Mr. Volker joins NeuroOne from Abbott Laboratories which acquired Cardiovascular Systems, Inc. in April 2023.
  • He began his career in healthcare and technology investment banking where he gained expertise in M&A, strategic planning, asset sales, and growth equity investments.
  • The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of awards that are not made under a stockholder approved equity plan.
  • The option award has an exercise price of $1.32 per share, the closing price of NeuroOne’s common stock on November 10, 2023, the date of the grant.

Trinity Capital Inc. Continues Life Sciences Growth, Hires Industry Veteran Ryan Kaeding as Managing Director

Retrieved on: 
Monday, December 18, 2023

PHOENIX, Dec. 18, 2023 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ: TRIN) ("Trinity" or the "Company"), a leading provider of diversified financial solutions to growth-stage companies, today announced the appointment of Ryan Kaeding as Managing Director, Life Sciences in San Diego, California.

Key Points: 
  • PHOENIX, Dec. 18, 2023 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ: TRIN) ("Trinity" or the "Company"), a leading provider of diversified financial solutions to growth-stage companies, today announced the appointment of Ryan Kaeding as Managing Director, Life Sciences in San Diego, California.
  • Mr. Kaeding, a veteran in the venture ecosystem, has been supporting venture capital-backed growth-stage companies for 20+ years.
  • "We are thrilled to welcome Ryan to our team in San Diego," said Rob Lake, Senior Managing Director, Life Sciences at Trinity.
  • Mr. Kaeding joins Trinity following 12 years of healthcare investment banking experience, most recently as a Managing Director at Raymond James and 10 years at Piper Sandler.

DuPont Collaborates with STMicroelectronics (ST) to Develop New Smart Wearable Device Concept for Monitoring Biosignals

Retrieved on: 
Thursday, November 2, 2023

WILMINGTON, Del., Nov. 2, 2023 /PRNewswire/ -- DuPont (NYSE:DD) today announced that DuPont™ Liveo™ Healthcare Solutions is collaborating with STMicroelectronics (NYSE: STM), a global leader in semiconductor technology serving customers across the spectrum of electronics applications, to develop a new smart wearable device concept for remote biosignal-monitoring.

Key Points: 
  • DuPont™ Liveo™ Healthcare and ST combine to create a new concept in wearable biosignal-monitoring devices that merges patient comfort with high performance.
  • WILMINGTON, Del., Nov. 2, 2023 /PRNewswire/ -- DuPont (NYSE:DD) today announced that DuPont™ Liveo™ Healthcare Solutions is collaborating with STMicroelectronics (NYSE: STM), a global leader in semiconductor technology serving customers across the spectrum of electronics applications, to develop a new smart wearable device concept for remote biosignal-monitoring.
  • "The wearable device concept that resulted from the collaboration between DuPont and ST is the DuPont™ Liveo™ Smart Biosensing Patch prototype, which employs multifunctional microsensors and control electronics from ST embedded in a flexible patch design from DuPont."
  • Whether for drug delivery or smart monitoring devices, DuPont™ Liveo™ Healthcare Solutions helps enable positive patient outcomes through increasingly advanced medical technology.

Neurolief Appoints Neurotechnology Business Leader Steve Beller as Chief Commercial Officer

Retrieved on: 
Wednesday, October 11, 2023

TAMPA, Fla., Oct. 11, 2023 /PRNewswire/ -- Neurolief, a global medical device company that is delivering life-changing neurotechnology innovations, today announced the appointment of Steve Beller, an experienced senior commercial leader in neurotechnology, as Chief Commercial Officer (CCO).

Key Points: 
  • TAMPA, Fla., Oct. 11, 2023 /PRNewswire/ -- Neurolief, a global medical device company that is delivering life-changing neurotechnology innovations, today announced the appointment of Steve Beller, an experienced senior commercial leader in neurotechnology, as Chief Commercial Officer (CCO).
  • Steve has a demonstrated history of success in building diverse and high-performing commercial organizations in the neuromodulation and mental health markets.
  • "I am delighted to welcome Steve to the Neurolief team," said Scott Drees, CEO of Neurolief.
  • "I am glad to welcome Steve to Neurolief team," said Amit Dar, Founder and Chief Technology Officer of Neurolief.

NeurAxis Highlights Strength of its Board of Directors

Retrieved on: 
Thursday, August 24, 2023

CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted the strength of its board of directors.

Key Points: 
  • CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted the strength of its board of directors.
  • “We are fortunate to have a board with a depth of experience in relevant areas to NeurAxis, including medical device commercialization, commercial insurance, and finance.
  • “We are excited to have this strength at the board level as we continue to develop and drive adoption of our IB Stim Therapy™,” concluded Mr. Carrico.
  • The Company’s Board of Directors includes:
    Ms. Keyser has more than 20 years of experience in executive roles in population health.

Shane Brown Promoted to President of GT Medical Technologies, Inc.

Retrieved on: 
Thursday, June 29, 2023

Since joining GT Medical Technologies, Inc. in May 2022, Mr. Brown has served as the Chief Commercial Officer, responsible for leading sales, marketing, customer operations and human resources.

Key Points: 
  • Since joining GT Medical Technologies, Inc. in May 2022, Mr. Brown has served as the Chief Commercial Officer, responsible for leading sales, marketing, customer operations and human resources.
  • We have the opportunity to drive adoption of this amazing therapy for patients with brain tumors who need better options," said Shane Brown, president of GT Medical Technologies.
  • Before joining GT Medical Technologies, Mr. Brown was the president and general manager of North America for Itamar Medical, a NASDAQ-listed company that was acquired by ZOLL Medical in December 2021.
  • Previously, Mr. Brown has held leadership roles in a host of other medical device companies including AngioDynamics, AGA Medical, St. Jude Medical, Topera and Abbott.

NeuroPace Announces CEO Transition

Retrieved on: 
Wednesday, June 28, 2023

MOUNTAIN VIEW, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Joel Becker as NeuroPace President & CEO and member of the Board of Directors effective July 10, 2023. Mr. Michael Favet will be stepping down as CEO and as a member of NeuroPace’s Board of Directors to pursue other opportunities. He has agreed to stay on as a consultant throughout the transition.

Key Points: 
  • Mr. Michael Favet will be stepping down as CEO and as a member of NeuroPace’s Board of Directors to pursue other opportunities.
  • He has agreed to stay on as a consultant throughout the transition.
  • “Joel brings a distinguished track record of successful commercial leadership and is highly qualified to lead NeuroPace as we move into our next phase of commercial expansion and corporate development,” said Frank Fischer, Chairman of the Board of Directors of NeuroPace.
  • “I am thrilled for the opportunity to join NeuroPace at this critical time in the Company’s history,” said Mr. Becker.

DexCare Appoints Robin Borg as Chief People Officer to Cultivate World-Class Talent to Fuel Growth

Retrieved on: 
Tuesday, June 27, 2023

“Robin has a long track record of cultivating talent to make teams more efficient, empowered and motivated,” said Derek Streat, CEO of DexCare. “We’ve always been focused on creating a purpose-driven culture because we value our talent above all else. The addition of Robin -- and her expertise and relentless passion -- enables DexCare to sustain its growth and build a team that is equipped to meet the mission of improving access to care.”

Key Points: 
  • DexCare , Inc., the leading patient demand and care access platform, has named Robin Borg, SPHR, as chief people officer (CPO).
  • As CPO, Borg strengthens DexCare’s recruiting and talent development process, and will further unify teams across locations.
  • With more than 30 years of experience in human resources, Borg plays an essential role to ensure DexCare attracts and retains top-notch talent to support the company’s continued growth.
  • “Robin has a long track record of cultivating talent to make teams more efficient, empowered and motivated,” said Derek Streat, CEO of DexCare.

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

Retrieved on: 
Wednesday, June 7, 2023

NEW HOPE, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Bill Little as EVP of Corporate Development and Strategy and Andrew Taylor as CFO. Mr. Taylor succeeds former CFO Michael Kaswan, who will continue as a consultant to the Company during a transition period.

Key Points: 
  • Mr. Taylor succeeds former CFO Michael Kaswan, who will continue as a consultant to the Company during a transition period.
  • “It’s an honor to welcome Bill and Andrew to our executive team, two highly experienced medical device industry executives with a strong appreciation for our partnership-driven innovation and growth strategy,” said David Hochman, Chairman, Chief Executive Officer and Founder of Orchestra BioMed.
  • We look forward to generating additional value for our stakeholders with the aid of Bill and Andrew’s leadership.
  • The appointment of Mr. Little marks the establishment of a formal corporate development function within Orchestra BioMed focused on driving strategy for additional potential strategic collaborations and pipeline expansion.